Company intelligence / Profile preview

Cambridge Heart

Tewksbury, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Cambridge Heart developed and commercialized non-invasive diagnostic tests for identifying patients at risk of sudden cardiac arrest, notably the Microvolt T-Wave Alternans™ test. The technology was based on research from MIT and was reimbursed by Medicare. Despite initial promise, the company faced persistent financial difficulties and ultimately ceased operations after auctioning its assets in 2014.

Therapeutic areas: Cardiovascular
Modalities: DeviceDiagnostic test
Industry: Physiological Monitoring

Partnerships

Partnership with Cardiac Science Corporation for nationwide program rollout of MTWA testing.

Beyond the preview

Go deeper on Cambridge Heart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambridge Heart.

Explore the full profile